Sharma K, Ziyadeh F N, Alzahabi B, McGowan T A, Kapoor S, Kurnik B R, Kurnik P B, Weisberg L S
Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
Diabetes. 1997 May;46(5):854-9. doi: 10.2337/diab.46.5.854.
Diabetic nephropathy is a common complication in patients with either type I or type II diabetes. The pathogenesis of diabetic nephropathy is thought to involve both metabolic and vascular factors leading to chronic accumulation of glomerular mesangial matrix. In this context, both transforming growth factor-beta (TGF-beta) and endothelin may contribute to these processes. To determine if diabetic patients demonstrate increased renal production of TGF-beta and endothelin, aortic, renal vein, and urinary levels of these factors were measured in 14 type II diabetic patients and 11 nondiabetic patients who were undergoing elective cardiac catheterization. Renal blood flow was measured in all patients to calculate net mass balance across the kidney. Diabetic patients demonstrated net renal production of immunoreactive TGF-beta1 (830 +/- 429 ng/min [mean +/- SE]), whereas nondiabetic patients demonstrated net renal extraction of circulating TGF-beta1 (-3479 +/- 1010 ng/min, P < 0.001). Urinary levels of bioassayable TGF-beta were also significantly increased in diabetic patients compared with nondiabetic patients (2.435 +/- 0.385 vs. 0.569 +/- 0.190 ng/mg creatinine, respectively; P < 0.001). Renal production of immunoreactive endothelin was not significantly increased in diabetic patients. In summary, type II diabetes is associated with enhanced net renal production of TGF-beta1, whereas nondiabetic patients exhibit net renal extraction of circulating TGF-beta1. Increased renal TGF-beta production may be an important manifestation of diabetic kidney disease.
糖尿病肾病是I型或II型糖尿病患者常见的并发症。糖尿病肾病的发病机制被认为涉及代谢和血管因素,导致肾小球系膜基质慢性积聚。在这种情况下,转化生长因子-β(TGF-β)和内皮素都可能促成这些过程。为了确定糖尿病患者肾脏中TGF-β和内皮素的产生是否增加,对14例II型糖尿病患者和11例接受择期心导管检查的非糖尿病患者的主动脉、肾静脉和尿液中这些因子的水平进行了测量。测量了所有患者的肾血流量,以计算肾脏的净质量平衡。糖尿病患者肾脏显示有免疫反应性TGF-β1的净产生(830±429 ng/分钟[平均值±标准误]),而非糖尿病患者肾脏显示对循环中的TGF-β1有净摄取(-3479±1010 ng/分钟,P<0.001)。与非糖尿病患者相比,糖尿病患者尿液中可进行生物测定的TGF-β水平也显著升高(分别为2.435±0.385与0.569±0.190 ng/毫克肌酐;P<0.001)。糖尿病患者肾脏中免疫反应性内皮素的产生没有显著增加。总之,II型糖尿病与肾脏中TGF-β1的净产生增加有关,而非糖尿病患者肾脏对循环中的TGF-β1有净摄取。肾脏TGF-β产生增加可能是糖尿病肾病的一个重要表现。